Profiel
Greg Hurlbut is the founder of Sionna Therapeutics, Inc. since 2019, holding the title of Senior Vice President-Discovery Research.
Former job includes Head-Protein Conformational Diseases at Genzyme Therapeutics Ltd. Education includes an undergraduate degree from the University of Massachusetts and a doctorate from Université Paris-Saclay.
Actieve functies van Greg Hurlbut
| Bedrijven | Functie | Begin |
|---|---|---|
| SIONNA THERAPEUTICS, INC. | Oprichter | 01-08-2019 |
Eerdere bekende functies van Greg Hurlbut
| Bedrijven | Functie | Einde |
|---|---|---|
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | - |
Opleiding van Greg Hurlbut
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
University of Massachusetts
University of Massachusetts Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Université Paris-Saclay
Université Paris-Saclay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
















